Kotak Invests in Cellogen Therapeutics

1 Minute Read Listen to Article
Share:    

May 18, 2026 21:50

x
Kotak Asset Managers invests Rs 20 cr in Cellogen Therapeutics. Funds to advance CAR'T clinical programs and expand gene therapy pipeline.
Mumbai, May 18 (PTI) Kotak Alternate Asset Managers on Monday said it has invested Rs 20 crore in NATCO Pharma-backed Cellogen Therapeutics.

The investment has been made through Kotak Life Sciences Fund I (KLSF-I), which typically invests in early- to growth-stage life sciences and healthcare businesses. Cellogen will use the funds to advance its CAR'T clinical programmes, expand its gene therapy pipeline, and strengthen manufacturing, a release said.







****

*Damroo raises Rs 5 crore from Hindustan Times



Music streaming platform Damroo on Monday announced a Rs 5 crore fund raise from Hindustan Times.

The funding will support the platform's efforts to scale artist development, audience growth, monetisation, and industry support initiatives, according to a statement.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume
  • IFCI
  • 84.63 (+ 19.99)
  • 23166160

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback